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Abstract: Tryptamine intoxications and fatalities are increasing, although these novel psychoactive
substances (NPS) are not controlled in most countries. There are few data on the metabolic pathways and enzymes involved in tryptamine biotransformation. 4-acetoxy-N,N-diisopropyltryptamine
(4-AcO-DiPT) is a synthetic tryptamine related to 4-hydroxy-N,N-diisopropyltryptamine (4-OHDiPT), 4-acetyloxy-N,N-dipropyltryptamine (4-AcO-DPT), and 4-acetoxy-N,N-dimethyltryptamine
(4-AcO-DMT). The aim of this study was to determine the best 4-AcO-DiPT metabolites to identify 4-AcO-DiPT consumption through human hepatocyte metabolism and high-resolution mass
spectrometry. 4-AcO-DiPT metabolites were predicted in silico with GLORYx freeware to assist in
metabolite identification. 4-AcO-DiPT was incubated with 10-donor-pooled human hepatocytes
and sample analysis was performed with reversed-phase liquid chromatography coupled with
high-resolution tandem mass spectrometry (LC-HRMS/MS) in positive- and negative-ion modes.
Software-assisted LC-HRMS/MS raw data mining was performed. A total of 47 phase I and II metabolites were predicted, and six metabolites were identified after 3 h incubation following ester hydrolysis,
O-glucuronidation, O-sulfation, N-oxidation, and N-dealkylation. All second-generation metabolites
were derived from the only first-generation metabolite detected after ester hydrolysis (4-OH-DiPT).
The metabolite with the second-most-intense signal was 4-OH-iPT-sulfate followed by 4-OH-DiPTglucuronide, indicating that glucuronidation and sulfation are common in this tryptamine’s metabolic
pathway. 4-OH-DiPT, 4-OH-iPT, and 4-OH-DiPT-N-oxide are suggested as optimal biomarkers to
identify 4-AcO-DiPT consumption.
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1. Introduction
Tryptamines are a class of new psychoactive substances (NPS) that share a core structure with the neurotransmitter serotonin, or 5-hydroxytryptamine (5-HT). Tryptamine’s
psychedelic effects are produced through agonism of the 5-HT2A and 5-HT2C receptors, with
additional contribution from other monoamine transporters [1–10]. Diverse tryptamine
structures have different receptor affinities and resultant effects. 4-AcO-DiPT is a synthetic
tryptamine related to 4-hydroxy-N,N-diisopropyltryptamine (4-OH-DiPT), 4-acetyloxyN,N-dipropyltryptamine (4-AcO-DPT), and 4-acetoxy-N,N-dimethyltryptamine (4-AcO-
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DMT), which currently are not controlled in many countries. 4-AcO-DiPT was identified
as early as July 2004, with charges against vendors selling the drug to the public; however, there were no convictions and there was no determination of the legal status of
4-AcO-DiPT [11]. Although the current use of psychedelics is low, tryptamine intake is
increasing [1,10] despite limited data on prevalence and patterns of intake. According to
psychonauts’ experiences, as reported on the Erowid website, 4-AcO-DiPT is available
online and typically administrated orally, with effects similar to those of hallucinogenic
mushrooms and 2-(4-bromo-2,5-dimethoxyphenyl)-ethanamine (2C-B) [12]. 4-AcO-DiPT
is a white powder available in freebase and HCl salt forms. Both are orally active, with
the lower molecular weight freebase being about 10% more potent than the same weight
of the HCl salt. 4-AcO-DiPT and 4-OH-DiPT have similar effects if taken orally, though
dosage might be different. Oral 4-AcO-DiPT doses start at 3–5 mg; 5–15 mg is considered a
“light” dose, while higher doses range between 25 and 40 mg. Users self-report 15–30 mg
doses, with onset of effects in 20–60 min, depending on dosage form and stomach contents,
and duration of 2–4 h. Its effects, which can appear within 1–4 h, are dose-dependent and
include hallucination, dissociation, confusion, and flashbacks, as reported on Erowid by
a 4-AcO-DPT user [12]. Over the last decade, there were few intoxication cases and even
fewer fatalities due to tryptamines reported in the European Union and North America,
although this is likely an underestimation due to missed detections. There are few data
on metabolic pathways and specific enzymes involved in tryptamine biotransformation,
but it appears that there is not a common metabolic pathway, with the nature and position
of substituents changing metabolism. Overall, psychedelic tryptamine use is increasing,
raising the importance of laboratory identification of specific metabolites to verify intake
and identify potential public health NPS outbreaks. The aim of this study was to determine the optimal 4-AcO-DiPT metabolite biomarkers of consumption for clinical and
forensic applications, using in silico metabolite prediction, human hepatocyte metabolism,
LC-HRMS/MS analysis, and software-assisted data mining.
2. Results
2.1. In Silico Metabolite Predictions
In silico metabolite predictions are reported in Supplementary Table S1. A total
of 47 phase I and II metabolites were predicted, with 10 first-generation metabolites
(pM 1–pM 10, by decreasing score) and 37 s-generation metabolites (pM X.1, pM X.4, by decreasing score, and pMX indicating the corresponding first-generation metabolite) (Table 1).
First-generation metabolites included hydroxylation, deisopropylation, carboxylation, ester
hydrolysis, glucuronidation, and deamination. Second-generation metabolites involved
phase I (hydroxylation, dealkylation, carboxylation, and deisopropylation) and phase II
(glucuronidation and sulfation) reactions. All predicted metabolites were incorporated in a
ddMS2 inclusion list to support LC-HRMS/MS analyses (Supplementary Table S1), and all
predicted metabolic transformations were incorporated in the list of potential reactions to
support automatic data mining.
2.2. 4-AcO-DiPT Fragmentation Pattern
The 4-AcO-DiPT fragmentation pattern is shown in Figure 1. In positive-ionization
mode, ions with m/z 202.0866 resulted from a loss of the diisopropyl amine group followed
by loss of the acetyl group producing ions with m/z 160.0758, the fragment with the most
intense signal. Further fragmentation yielded ions with m/z 132.0808 then 115.0539 through
carbon monoxide and ammonia losses, respectively. Ion m/z 117.0573 was a radical cation
typically yielded from hydroxylindole alkylamines [13]. α- and β-cleavage at the nitrogen
of the ethylamine chain yielded fragments with m/z 114.1275 and 102.1278, respectively.
Fragments with m/z 72.0805 were further produced by isopropyl loss from ions with
m/z 114.1275. In addition, the fragments with m/z 259.1815 in negative ionization mode
indicate an acetyl loss on the parent drug.
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Table 1. Molecular structure, elemental composition, metabolic transformation, and predictive score
of in silico-predicted 4-AcO-DiPT metabolites.
Predicted
Metabolite (pM)

Transformation

Elemental Composition

Score (%)

pM1
pM1.1
pM1.2
pM1.3
pM1.4

N-Hydroxylation
O-Glucuronidation
N-Deisopropylation
Hydroxylation
Hydroxylation (C1”)

C18 H27 N2 O3
C25 H30 N2 O8
C16 H21 NO3
C19 H28 NO4
C18 H26 N04

63
30
22
22
21

pM2
pM2.1
pM2.2
pM2.3

Hydroxylation (C2”)
O-Sulfation
O-Glucuronidation
Dealkylation

C18 H26 N2 O3
C18 H24 N3 O7 S
C24 H32 N2 O10
C17 H24 N2 O2

63
60
39
21

pM2.4
pM2.5

Hydroxylation (C11)
Carboxylation (C9)

C19 H26 N2 O4
C19 H24 N2 O5

21
21

pM3
pM3.1
pM3.2
pM3.3
pM3.4

Deisopropylation
Hydroxylation (C1”)
Depropylation
N-Hydroxylation
N-Deisopropylation

C15 H20 N2 O2
C16 H20 N2 O3
C13 H14 O3
C15 H20 N2 O3
C12 H14 N2 O2

63
35
35
35
35

pM4
pM4.1
pM4.2

Hydroxylation (acetyl)
O-Glucuronidation
O-Sulfation

C18 H26 N2 O3
C23 H32 N2 09
C17 H24 N2 06 S

34
28
24

pM5
pM5.1
pM5.2
pM5.3
pM5.4

Carboxylation (acetyl)
O-Glucuronidation
N-Hydroxylation
Deisopropylation
Hydroxylation (C1”)

C19 H26 N2 O3
C26 H36 N2 O9
C18 H25 N2 O5
C15 H18 N2 04
C18 H24 N2 O5

34
31
20
20
20

pM6
pM6.1
pM6.2
pM6.3
pM6.4

Ester hydrolysis
O-Sulfation
O-Glucuronidation
Hydroxylation (C1”)
N-Hydroxylation

C19 H26 N2 O
C16 H24 N2 O4 S
C22 H32 N2 O7
C16 H24 N2 O2
C16 H25 N2 O2

34
32
29
20
20

pM7

Hydroxylation (C2)

C16 H24 N2 O2

25

pM8

N-Glucuronidation

C12 H13 NO3

20

pM9

Deamination (to
aldehyde)

C12 H13 NO3

20

pM10

Deamination (to alcohol)

C12 H11 NO3

20

2.3. Metabolite Identification
LC-HRMS data were automatically processed to produce a list of six potential metabolites that were manually checked by the operators. The 4-AcO-DiPT LC-HRMS peak area
was 3.00 × 107 in the 3 h incubation with hepatocytes, i.e., 375 times lower than that of the
0 h incubation (1.12 × 1010 ). Six metabolites were identified after 3 h incubation following
ester hydrolysis, O-glucuronidation, O-sulfation, N-oxidation, and N-dealkylation. All
second-generation metabolites were derived from the only first-generation metabolite
detected, which was produced by ester hydrolysis (4-OH-DiPT, M4). The metabolites
are listed from M1 to M6 by ascending retention time (Table 2). The five remaining
metabolites all derived from M4 with further phase I and II transformations, including
N-deisopropylation (4-OH-iPT, M1 and 4-OH-iPT-sulfate, M2) and N-oxidation at the ethylamine chain (4-OH-DiPT-N-oxide, M6), and O-sulfation (M2 and 4-OH-DiPT-sulfate, M5)
and O-glucuronidation (4-OH-DiPT-glucuronidate, M3) in the indole ring. The fragmentation pattern of 4-AcO-DiPT metabolites is shown in Figure 1. The metabolic pathway of the
major metabolites is suggested in Figure 2. An extracted-ion chromatogram of 4-AcO-DiPT
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Table 2. Metabolic transformation, retention time (RT), accurate mass of molecular ion (hydrogen
adduct in positive-ionization mode [M + H]+ ), elemental composition, deviation from theoretical
accurate mass, and liquid chromatography–high-resolution mass spectrometry peak area of 4-AcODiPT and metabolites after 3 h incubation with human hepatocytes (HESI positive mode, HESI
negative mode).
ID

Transformation

RT (min)

[M + H]+

Elemental
Composition

Mass Error
(ppm)

Peak Areas
(HESI+, HESI−)

M1

Ester hydrolysis + N-Deisopropylation

6.31

219.1489

C13 H18 N2 O

−1.21

1.10 × 108

M2

Ester hydrolysis + N-Deisopropylation
+ O-Sulfation

7.24

299.1057

C13 H18 N2 O4 S

−1.23

3.50 × 107 , 5.90 × 107

M3

Ester hydrolysis + O-Glucuronidation

8.30

437.2277

C22 H32 N2 O7

−1.45

2.94 × 108 , 2.60 × 107

M4

Ester hydrolysis

11.82

261.1955

C16 H24 N2 O

−2.25

4.19 × 109

M5

Ester hydrolysis + O-Sulfation

12.11

341.1525

C16 H24 N2 O4 S

−1.42

4.47 × 107 , 2.79 × 107

12.53

277.1907

C16 H24 N2 O2

−1.35 6

C18 H26 N2 O2

of 12
−62.67

M6
Parent
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Figure 2. Suggested metabolic fate of 4-AcO-DiPT. Bold indicates major transformations.
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Figure 3. Extracted-ion chromatogram of 4-AcO-DiPT and metabolites in positive-ionization mode
obtained after 3 h incubation with human hepatocytes. Mass tolerance: 5 ppm; m/z values: 219.1489,
261.1955,
299.1057,
303.2059, 341.1525,
and 437.2277.
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signal with a base peak at m/z 261.1954. 4-OH-DiPT transformation occurred with the loss
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2.3.1. Phase I Metabolites
Ester Hydrolysis
Among the detected metabolites, M4, eluted at 11.82 min, generated the most intense
signal with a base peak at m/z 261.1954. 4-OH-DiPT transformation occurred with the loss
of the acetyl group and with hydrolysis occurring in the hydroxyl group of the indole ring,
as demonstrated by the production of fragments with m/z 160.0753, 114.1274, and 117.0573.
The fragments from negative-ionization mode at m/z 132.0243, 114.1275, 132.0804, and
72.0806 showed that the indole core and ethylamine chains were intact. The acetyl loss is
indicated by the mass shift of +42.0104 Da from the parent and a difference of -2C -2H -1O
on the elemental composition.
M1, M2, M3, M5, and M6 were produced after ester hydrolysis and other metabolic
reactions. M3 was detected as a double peak with the same fragmentation pattern.
Ester Hydrolysis and N-Deisopropylation
M1 eluted at 6.31 min, and was formed after N-deisopropylation following ester
hydrolysis. A fragment with m/z 160.0752 in the MS/MS spectrum clearly identifies that
this reaction occurred in the isopropyl group. 4-OH-iPT revealed a mass shift of +84.0570 Da
and a difference of elemental composition of -5C -8H–1O proves this metabolic reaction.
Ester Hydrolysis and N-Oxidation
M6 was detected at 12.53 min and was produced by oxidation on the indole ring after
ester hydrolysis. Fragments with m/z 160.0752, 107.0492, and 115.0539 showed that this
transformation did not occur in the indole ring, but instead in the diisopropyl amine group
of the molecule. This metabolite presented a mass shift of +26.0152 Da and a difference in
elemental composition of -2C -2H. The retention time of 4-OH-DiPT-N-oxide was later than
that of M4 (4-OH-DiPT), indicating N-oxidation [14–16].
2.3.2. Phase II Metabolites
Ester Hydrolysis and O-Glucuronidation
M3, detected at 8.20 min, had the second-most-intense signal. This metabolite was
formed after ester hydrolysis and glucuronidation. 4-OH-DiPT-glucuronidate presented
a mass shift of −134.0218 Da, differing by +4C +6H +5O from the elemental composition
of the parent drug. The presence of fragments with m/z 160.0753 and 114.1274 clearly
indicates no transformation in the indole core or the ethylamine chain. Actually, the signal
that was detected in negative ionization mode suggests that a glucuronidation reaction
occurred.
Ester Hydrolysis and O-Sulfation
M5 eluted at 12.11 min, with fragments having m/z 160.0752 and 115.0539 indicating
no reaction at the indole core or the ethylamine chain. 4-OH-DiPT-sulfate showed a mass
shift of −37.9466 Da and a difference of -2C -2H +2O +1S on its elemental composition.
Ester Hydrolysis, N-Deisopropylation, and O-Sulfation
M2, eluting at 7.24 min, resulted from ester hydrolysis, N-deisopropylation, and
sulfation (produced by M1 O-sulfation). The fragments with m/z 120 prove that no changes
were made in the indole core. 4-OH-iPT-sulfate had a mass shift of +4.1002 Da and a
difference of -5C -8H +2O +1S in its elemental composition. M2 produced fragments with
m/z 219.1487 by sulfate loss, and similar fragments to those of M1.
The fact that a signal was also identified in negative ionization mode suggests that a
sulfation reaction occurred to generate both metabolites (M2 and M5).
3. Discussion
In silico metabolite predictions alone are not sufficient to identify the metabolism of
specific drugs; however, compilation of HRMS/MS inclusion and exclusion lists and a list of
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potential metabolic transformations is key to successful Compound Discoverer processing
workflow (Supplementary Table S1) and for aiding manual metabolite identification. All
six metabolites were predicted. The main phase I and II reactions occurred in the hydroxyl
group of the indole ring and in the isopropyl group after ester hydrolysis.
4-AcO-DiPT was incubated with human hepatocytes, which have been proven more
suitable for metabolite profiling than human liver microsomes [17]. Hepatocytes are more
representative of the physiological liver environment containing both phase I and II drugmetabolizing enzymes, cofactors, and drug transporters [18]. All of these factors allow a
better estimation of in vivo metabolism.
The M4 signal was the most intense metabolite signal detected 3 h after incubation
with hepatocytes, followed by glucuronidation generating M3. Interestingly, the most
intense metabolite (M4) was also detected in the control samples without hepatocytes at
0 and 3 h and at 0 h incubation with hepatocytes but at a much lower intensity than after
3 h incubation, meaning that, although M4 is formed through an enzymatic reaction, it is
also spontaneously formed during incubation to a lesser extent. This indicates that M4
formation was overestimated in our experiments. When analyzing authentic samples,
digestion (with β-glucuronidase/sulfatase) is preferred to increase the M4 signal. To
further understand where the glucuronidation occurred in M3, the 3 h incubations with
hepatocytes was reanalyzed after enzymatic hydrolysis with β-glucuronidase, suggesting
which part of the molecule was glucuronidated. β-Glucuronidase catalyzes the hydrolysis
of O-glucuronides and not N-glucuronides. Comparing the control sample (same hydrolysis
conditions but without β-glucuronidase) to the sample with β-glucuronidase, M3 was not
present, revealing that the reaction occurred at the hydroxyl group of the molecule and not
on the amine group.
An additional consideration is that samples were resuspended in a ratio of 80:20
mobile phase (A:B) to guarantee maximum recovery of the analyte. This can explain the
double peak detected for M3. Better peak shapes would be obtained if samples were
resuspended with a lower percentage of acetonitrile (mobile phase B). To assure that the
double peak was not an isomer, another test was made using a ratio of 95:5 mobile phase
(A:B) where no double peak was detected.
Since the parent drug is most likely degraded as the acetyl group is eliminated quickly,
toxicologists could report 4-OH-DiPT (M4)-positive cases as from 4-AcO-DiPT intake. The
second-most-intense metabolite was M3 (4-OH-DiPT-glucuronide) followed by M1 (4-OHiPT), indicating that glucuronidation and dealkylation are common in this tryptamine’s
metabolic pathway. Others propose that tryptamines do not have a common metabolic
pathway and that metabolism changes depending on the nature and position of their
substituents, with demethylation, hydroxylation, and dealkylation being the most common
phase I reactions, followed by glucuronidation or sulfation [19–24]. 4-OH-DiPT, 4-OH-iPT,
and 4-OH-DiPT-N-oxide are proposed as biomarkers of 4-AcO-DiPT consumption, but the
rapid enzymatic hydrolysis and lower spontaneous hydrolysis of 4-AcO-DiPT to 4-OHDiPT might create a problem in discerning 4-AcO-DiPT from 4-OH-DiPT consumption. If
the parent drug is present even in low concentrations, the ingested drug would be clear,
but there is no available information regarding detection of this drug in authentic samples.
These results require in vivo confirmation, which is challenging due to the lower prevalence
indicated by the small number of 4-AcO-DiPT seizures in recent years.
4. Materials and Methods
4.1. In Silico Metabolites Prediction
4-AcO-DiPT metabolites were predicted with the online GLORYx freeware [25,26].
The metabolite list was generated using the 4-AcO-DiPT with the “phase I and phase II
metabolism” option (Table 1, 1st generation). Metabolites with a score higher than 0.40
were selected and reprocessed to simulate a second-step metabolism reaction
(Table 1, 2nd generation); the second-generation metabolite score was multiplied by the
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first-generation metabolite score and scores higher than 0.20 were added to the inclusion
list (Supplementary Table S1).
4.2. Chemicals and Reagents
4-AcO-DiPT was obtained from Cayman Chemical (Ann Arbor, MI, USA) and diclofenac was acquired from Sigma Aldrich (Milan, Italy). Stock standards of these chemicals were prepared to 1 mg/mL in LC-MS-grade methanol (Carlo Erba; Cornaredo, Italy).
Standards were stored at –20 ◦ C until analysis. Ten-donor-pooled cryopreserved human
hepatocytes, thawing medium (TM), and 0.4% trypan blue were purchased from Lonza
(Basel, Switzerland). l-Glutamine, HEPES (2-[4-(2-hydroxyethyl)-1-piperazinyl]ethanesulfonic acid), and Williams’ Medium E were obtained from Sigma Aldrich. l-Glutamine
and HEPES were dissolved in Williams’ Medium E to 2 and 20 mmol/L, respectively, prior
to analysis. The supplemented Williams’ Medium E (sWME) was stored at 4 ◦ C until
incubation. LC-MS-grade acetonitrile, water, and formic acid were obtained from Carlo
Erba (Cornaredo, Italy).
4.3. Hepatocytes Incubation
Incubations were conducted as previously described, with small adjustments [27].
Hepatocytes, thawed at 37 ◦ C, were lightly mixed with 50 mL TM in a 50 mL polypropylene
conical tube maintained at the same temperature. The tube was centrifuged at 100× g
for 5 min and the pellet washed with 50 mL sWME at 37 ◦ C. After centrifugation under
the same conditions, cells were resuspended in 2 mL sWME. Hepatocyte viability was
evaluated with the trypan blue exclusion test, and sWME volume adjusted to 2 × 106
viable cells/mL. Incubations were prepared in sterile 24-well culture plates with 250 µL
hepatocyte suspension and 250 µL 4-AcO-DiPT at 20 µmol/L in sWME at 37 ◦ C. Metabolic
reactions were then interrupted with 500 µL ice-cold acetonitrile. Negative controls, i.e.,
hepatocytes in sWME without 4-AcO-DiPT and 4-AcO-DiPT in sWME without hepatocytes,
were incubated for 3 h under the same conditions. Diclofenac was also incubated under
the same conditions to ensure proper metabolic activity.
4.4. Sample Preparation
For sample preparation, 100 µL hepatocyte supernate was vortexed with 100 µL
acetonitrile, centrifuged at 15,000× g for 10 min at room temperature, and the supernates
were dried under nitrogen at 37 ◦ C. Residues were reconstituted with 150 µL mobile phase
A (MPA): mobile phase B (MPB) (8:2 v/v), mixed well, and centrifuged for 10 min at
15,000× g at room temperature, and the supernates were transferred into glass inserts in
LC autosampler vials. The sample injection volume was 15 µL.
4.5. Instrumental Conditions
LC-HRMS/MS analyses were performed on a DIONEX UltiMate 3000 liquid chromatograph coupled with a Q-Exactive quadrupole-Orbitrap hybrid high-resolution mass spectrometer with a heated-electrospray-ionization (HESI) source (Thermo Scientific, Waltham,
MA, USA).
4.6. Liquid Chromatography
Chromatographic separation occurred on a Kinetex® Biphenyl column (150 × 2.1 mm,
2 µm) (Phenomenex, Castel Maggiore, Italy) maintained at 37 ± 1 ◦ C. The 30 min run
utilized 0.1% formic acid in water (MPA) and 0.1% formic acid in acetonitrile (MPB) at a
0.4 mL/min flow rate. The gradient was started at 5% MPB for 2 min, increased to 25%
MPB by 18 min, further increased to 95% MPB within 2 min, and held for 5 min. The return
to initial conditions occurred within 0.1 min, followed by a 4.9 min equilibration, for a total
runtime of 30 min. Autosampler temperature was 10 ± 1 ◦ C.
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4.7. Mass Spectrometry Conditions
Samples were injected twice, once in positive- and once in negative-ionization mode.
HESI source parameters were 50 sheath-gas flow rate, 10 auxiliary-gas flow rate, ±3 kV
spray voltage, 300 ◦ C capillary- and auxiliary-gas heater temperature, and 50 S-lens radio
frequency; sweep gas was not applied. The orbitrap was calibrated prior to analysis, with
a lock mass list for better accuracy. Data were acquired from 1 to 25 min in full-scan
HRMS (FullMS)/data-dependent MS/MS (ddMS2 ) mode. The FullMS acquisition range
was m/z 120–700 with a resolution of 70,000 at full width at half maximum (FWHM) at
m/z 200. The automatic gain control (AGC) target was 106 and maximum injection time
(IT) 200 ms. Up to 5 ddMS2 scans were triggered, with a dynamic exclusion of 2.0 s and
an intensity threshold of 104 for each FullMS scan, depending on a priority inclusion list
of putative metabolites (Supplementary Table S1) based on in silico predictions and the
metabolic fate of 4-AcO-DiPT analogues (Table 1). Other ions not in the inclusion list might
also trigger ddMS2 scans. Additionally, background m/z values with high intensity were
assessed during injection of blank controls and compiled in an exclusion list in positiveand negative-ion modes. The ddMS2 isolation window was m/z ± 1.2 with a resolution of
17,500 and the normalized collision energy (NCE) was 30, 60, and 90 a.u. The ddMS2 AGC
target was 2 × 105 and maximum IT was 64 ms.
4.8. Final Metabolite Identification
LC-HRMS data were processed with Compound Discoverer (v. 3.1.1.12) from Thermo
Scientific (Waltham, MA, USA), using a partially automated approach. Briefly, the ions
detected in HRMS were compared to a list of theoretical metabolites (intensity threshold,
5 × 103 ; mass tolerance, 5 ppm). The HRMS/MS spectra and theoretical elemental composition of the ions were compared to online databases (intensity threshold, 105 ; HRMS
mass tolerance, 5 ppm; HRMS/MS mass tolerance, 10 ppm). The chromatographic peaks
detected in controls with a similar or higher intensity to that of the peaks detected in the
samples were filtered out.
5. Conclusions
This study marks the first characterization of the 4-AcO-DiPT metabolic profile in
human hepatocytes using in silico metabolite predictions, LC-HRMS/MS analysis, and
software-assisted data mining. We identified six metabolites through ester hydrolysis
followed by N-Deisopropylation, O-sulfation, O-glucuronidation, and/or N-Oxidation. We
recommend 4-OH-DiPT, 4-OH-iPT, and 4-OH-DiPT-N-oxide as metabolite biomarkers of
4-AcO-DiPT consumption in clinical and forensic toxicology. We propose incorporation
of HRMS/MS fragmentation patterns into the online libraries mzCloud and HighResNPS.
These findings underscore the value of experimental data and demonstrate how challenging
it is to predict NPS metabolism. Our in vitro model offers preliminary findings about 4-AcODiPT human metabolism; however, these findings should be verified using samples from
authentic positive cases. These data enable analytical toxicologists to identify 4-AcO-DiPT
exposure cases.
Supplementary Materials: The following supporting information can be downloaded at: https:
//www.mdpi.com/article/10.3390/metabo12080705/s1, Table S1: Inclusion list for the MS/MS
data-dependent acquisition.
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